Wilms Tumor Protein (WT33 or WT1) Overviewed for Pipeline Assessment and Development- H1 2017


Published on : Jul 06, 2017

Albany, New York, July 6, 2017: The Wilms tumor protein has the tumor suppression property that makes it popular. Hence, the therapeutic development for this protein is analyzed in an intelligent report published by Market Research Hub (MRH) titled as “Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2017”. It outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development, cell survival, and plays an essential role in the urogenital system development. The protein is a tumor suppressor and has an oncogenic role in tumor formation as well as regulates the expression of numerous target genes, including EPO. The report covers products from therapy areas oncology which include indications such as Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Solid Tumor, Ovarian Cancer, and other.

The report initiates with the Wilms tumor protein (WT33 or WT1) complete overview and its therapeutic development, assessment and companies involved in its therapeutic development. The analyzed WT33 or WT1 therapeutic development details the products under development by stage of development, therapy area, indication, and companies. Further, the Wilms Tumor Protein therapeutic assessment shows the assessment by route of administration and molecule type. The report also lists the major companies involved in the therapeutic development of wilms tumor protein. Some of the key players enclosed in the study include names like GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Sumitomo Dainippon Pharma Co Ltd and Vaximm AG.

In the next section the main drugs of WT33 or WT1 under its therapeutic development are listed along with product description, mechanism of action and R&D progress. The primary featured drugs includes, DSP-7888, galinpepimut-S, GSK-2130579A, INO-5401, OCV-501, Vaccine for Oncology, Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome, Vaccine to Target Wilms Tumor Protein for Oncology, Vaccine to Target WT1 for Leukemia, Vaccine to Target WT1 for Oncology, VXM-06, WT-2725, and WT-4869.

Lastly, a brief introduction of the dormant products, the milestone products and the featured news and press releases are provided in this intelligent research report for complete evaluation. The research concludes by providing, and thus validating the various resources of the study along with the numerous tables and figures that help in easy and early decision making by the industry experts and decision makers.

Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157719

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-518-621-2074

+1-866-997-4948US Toll Free

Email : sales@marketresearchhub.com

Back To Top